Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2025Cancer

Treatment research after failure of fourth‐line standard therapy for advanced gastrointestinal stromal tumors: A review

View Full Paper
Ask AI
Bookmark
Share

Authors

XSXincheng SuSHShichai HongZYZhenrong Yang

Discussion

Loading...

Member takes

Overview

Treatment strategies improve efficacy in gastrointestinal stromal tumors after fourth-line therapy failure, suggesting new options are needed.

Key Points

  • Imatinib resistance leads to high spatiotemporal heterogeneity, impacting GIST treatment outcomes.
  • Recent advances in treatment strategies focus on radiotherapy and immunotherapy to enhance efficacy.
  • This review covers standard treatment protocols and emerging therapies for patients with progressive GISTs.
  • Clinical decision-making benefits from new evidence presented at international conferences on GIST management.

Cite This Study

Su et al. (2025) studied this question.

synapsesocial.com/papers/69402a7e2d562116f2902147https://doi.org/10.1002/cncr.70066
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance2025 · 6 citations
  2. 2Integrating surgery and targeted therapies in the management of recurrent/metastatic gastrointestinal stromal tumors2025
  3. 3Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions2026
  4. 4Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies2026 · 2 citations
  5. 5Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape2026